INS and hydrops fetalis: The results of this study can be summarized as follows: (i) despite worse insulin sensitivity and worse DM compensation in MET-treated patients, MET-treatment was independently associated with both better quality of life and improved outcome in advanced HFrEF patients with DM; (ii) MET treatment was associated with better outcome regardless of HF severity or compensation of diabetes.